U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07363486) titled 'Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer' on Dec. 05, 2025.
Brief Summary: PSMA is an ideal target for the precise diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted compound. This study aims to investigate the safety and efficacy of different doses of 225Ac-labeled LNC1011 in the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) and to explore the optimal therapeutic dose.
Study Start Date: April 01, 2025
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: ...